lisdexamfetamine dimesylate

Known as: Lis dexamfetamine Dimesylate, Lisdexamfetamine Dimesylate [Chemical/Ingredient], Dimesylate, Lisdexamfetamine 
The dimesylate form and prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS… (More)
National Institutes of Health

Related topics

Related topics

14 relations

Broader (3)

Central Nervous System StimulantsDopamine Uptake InhibitorsLisdexamfetamine

Narrower (3)

ElvanseNRP104Vyvanse
In Bloodagonistsanalogs & derivativesantagonists & inhibitors
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
OBJECTIVE To examine lisdexamfetamine dimesylate (LDX) efficacy and safety versus placebo in adolescents with attention-deficit… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
These studies investigated the absorption and metabolic conversion of lisdexamfetamine dimesylate (LDX), a prodrug stimulant that… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant and is indicated for the treatment of attention-deficit… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.
The objective of this study is to determine the safety, tolerability and abuse liability of single intravenous (i.v.) doses of… (More)
Is this relevant?
2009
2009
Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
OBJECTIVE To evaluate the long-term safety and effectiveness of lisdexamfetamine dimesylate (LDX) in the treatment of adults with… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
OBJECTIVE To evaluate the efficacy and safety of 30, 50, and 70 mg/day lisdexamfetamine dimesylate compared with placebo in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
OBJECTIVE To evaluate the pharmacokinetics of lisdexamfetamine dimesylate (LDX; Vyvanse) in fasting healthy adult volunteers… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study
BACKGROUND Lisdexamfetamine dimesylate is a therapeutically inactive prodrug in which d-amphetamine is covalently bound to l… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel…
BACKGROUND Lisdexamfetamme dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal of… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A common coding variant in CASP8 is associated with breast cancer risk
The Breast Cancer Association Consortium (BCAC) has been established to conduct combined case-control analyses with augmented… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 1
Is this relevant?